You’ll have a hard time finding a more modest man than Dennis Wahr, president and CEO of Nuvaira. But when asked what company he sees as being poised to establish the Interventional Pulmonology industry Wahr says Nuvaira might be the one. Nuvaira’s Targeted Lung Denervation, or TLD, is a non-surgical procedure that interrupts overactive nerve signals and may reduce obstructive airway symptoms, helping you to breathe easier. Could Nuvaira be the company to finally set the cement in the foundation of Interventional Pulmonology? Or will Nuvaira build upon the success of Pulmonx and Inspire, two other respiratory companies making great strides in commercializing new technology. In this podcast, Dennis Wahr discusses Nuvaira’s fund-raising success and what it means for its future (could an IPO be possible?) He also gives tips to other companies presenting at the May 17 Respiratory Innovation Summit in Dallas, another Healthegy-organized event. AttendRIS.com
Dennis Wahr, MD
President & CEO
Dennis Wahr, MD joined Nuvaira in September 2012, with a unique background in serial medical device development, clinical evaluation and commercialization experience.
Prior to joining Nuvaira, Dr. Wahr co-founded Lutonix in 2007 and served as its President and CEO until CR Bard acquired the company in December 2011. Preceding its acquisition, Lutonix developed a unique drug coated balloon angioplasty technology for the treatment and prevention of vascular stenosis caused by atherosclerosis. Prior to Lutonix, Dr. Wahr co-founded Velocimed in 2001, and served as its President and CEO until its acquisition by St. Jude Medical in 2005.
As a company CEO, Dr. Wahr has wide-ranging experience with both the European regulatory authorities and the US FDA. His companies have sponsored 9 clinical trials involving more than 1500 patients leading to approvals for 4 unique and innovative medical products.
Dr. Wahr has served on the board of directors of several medical device companies including Accumetrics, IDev, Velocimed and Lutonix, and he currently serves as chairman of the board for Intact Vascular. Additionally, Dr. Wahr spent two years as a Managing Director with RiverVest Ventures focusing on capital investments in emerging medical technology companies.
Dr. Wahr received a Bachelor of Arts from Albion College and his Medical Degree from Wayne State University School of Medicine. He did a fellowship in interventional cardiology at the University of California, San Francisco and is currently board certified in interventional cardiology. He spent more than 14 years in clinical practice and served as the Chief of Cardiology at the Michigan Heart and Vascular Institute in Ann Arbor, MI prior to launching his entrepreneurial career.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.